tbuckley/cabot-search huggingface dataset:
Hyperthyroidism
Authors: Sun Y. Lee, Elizabeth N. Pearce
Journal: JAMA (2023)

Importance Overt hyperthyroidism, defined as suppressed thyrotropin (previously thyroid-stimulating hormone) and high concentration of triiodothyronine (T 3 ) and/or free thyroxine (FT 4 ), affects approximately 0.2% to 1.4% of people worldwide. Subclinical hyperthyroidism, defined as low concentrations of thyrotropin and normal concentrations of T 3 and FT 4 , affects approximately 0.7% to 1.4% of people worldwide. Untreated hyperthyroidism can cause cardiac arrhythmias, heart failure, osteoporosis, and adverse pregnancy outcomes. It may lead to unintentional weight loss and is associated with increased mortality. Observations The most common cause of hyperthyroidism is Graves disease, with a global prevalence of 2% in women and 0.5% in men. Other causes of hyperthyroidism and thyrotoxicosis include toxic nodules and the thyrotoxic phase of thyroiditis. Common symptoms of thyrotoxicosis include anxiety, insomnia, palpitations, unintentional weight loss, diarrhea, and heat intolerance. Patients with Graves disease may have a diffusely enlarged thyroid gland, stare, or exophthalmos on examination. Patients with toxic nodules (ie, in which thyroid nodules develop autonomous function) may have symptoms from local compression of structures in the neck by the thyroid gland, such as dysphagia, orthopnea, or voice changes. Etiology can typically be established based on clinical presentation, thyroid function tests, and thyrotropin-receptor antibody status. Thyroid scintigraphy is recommended if thyroid nodules are present or the etiology is unclear. Thyrotoxicosis from thyroiditis may be observed if symptomatic or treated with supportive care. Treatment options for overt hyperthyroidism from autonomous thyroid nodules or Graves disease include antithyroid drugs, radioactive iodine ablation, and surgery. Treatment for subclinical hyperthyroidism is recommended for patients at highest risk of osteoporosis and cardiovascular disease, such as those older than 65 years or with persistent serum thyrotropin level less than 0.1 mIU/L. Conclusions and Relevance Hyperthyroidism affects 2.5% of adults worldwide and is associated with osteoporosis, heart disease, and increased mortality. First-line treatments are antithyroid drugs, thyroid surgery, and radioactive iodine treatment. Treatment choices should be individualized and patient centered.
Tezepelumab decreases airway epithelial IL‐33 and T2‐inflammation in response to viral stimulation in patients with asthma
Authors: A. Sverrild, S. Cerps, J. J. Nieto‐Fontarigo, S. Ramu, M. Hvidtfeldt, M. Menzel, J. Kearley, J. M. Griffiths, J. R. Parnes, C. Porsbjerg, L. Uller
Journal: Allergy (2023)

Abstract Background Respiratory virus infections are main triggers of asthma exacerbations. Tezepelumab, an anti‐TSLP mAb, reduces exacerbations in patients with asthma, but the effect of blocking TSLP on host epithelial resistance and tolerance to virus infection is not known. Aim To examine effects of blocking TSLP in patients with asthma on host resistance (IFNβ, IFNλ, and viral load) and on the airway epithelial inflammatory response to viral challenge. Methods Bronchoalveolar lavage fluid (BALF, n = 39) and bronchial epithelial cells (BECs) were obtained from patients with uncontrolled asthma before and after 12 weeks of tezepelumab treatment ( n = 13) or placebo ( n = 13). BECs were cultured in vitro and exposed to the viral infection mimic poly(I:C) or infected by rhinovirus (RV). Alarmins, T2‐ and pro‐inflammatory cytokines, IFNβ IFNλ, and viral load were analyzed by RT‐qPCR and multiplex ELISA before and after stimulation. Results IL‐33 expression in unstimulated BECs and IL‐33 protein levels in BALF were reduced after 12 weeks of tezepelumab. Further, IL‐33 gene and protein levels decreased in BECs challenged with poly(I:C) after tezepelumab whereas TSLP gene expression remained unaffected. Poly(I:C)‐induced IL‐4, IL‐13, and IL‐17A release from BECs was also reduced with tezepelumab whereas IFNβ and IFNλ expression and viral load were unchanged. Conclusion Blocking TSLP with tezepelumab in vivo in asthma reduced the airway epithelial inflammatory response including IL‐33 and T2 cytokines to viral challenge without affecting anti‐viral host resistance. Our results suggest that blocking TSLP stabilizes the bronchial epithelial immune response to respiratory viruses.
Selenium and Vitamin E for Prevention of Non–Muscle-Invasive Bladder Cancer Recurrence and Progression
Authors: Richard T. Bryan, Sarah J. Pirrie, Ben Abbotts, Shanna Maycock, Vinnie During, Carolyn Lewis, Margaret Grant, Deborah Bird, Adam J. Devall, D. Michael A. Wallace, Nicholas D. James, Lucinda J. Billingham, Maurice P. Zeegers, K. K. Cheng, Gun Choudry, Sikander Khwaja, Ken Desai, Kieran P Jefferson, Lawrence A Emtage, Aniruddha Chakravarti, Michael C Foster, B Dev Sarmar, Christopher J Luscombe, D Michael A Wallace, Nicholas J James, Peter W Cooke, Krzysztof Kadow, John Parkin, Adel Makar
Journal: JAMA Network Open (2023)

Selenium and vitamin E have been identified as promising agents for the chemoprevention of recurrence and progression of non-muscle-invasive bladder cancer.
Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms
Authors: Jaime de la Fuente, Arjun Chatterjee, Jacob Lui, Avinash K. Nehra, Matthew G. Bell, Ryan J. Lennon, Blake A. Kassmeyer, Rondell P. Graham, Hiroki Nagayama, Phillip J. Schulte, Karen A. Doering, Adriana M. Delgado, Santhi Swaroop Vege, Suresh T. Chari, Naoki Takahashi, Shounak Majumder
Journal: JAMA Network Open (2023)

Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that can give rise to pancreatic cancer (PC). Limited population data exist on their prevalence, natural history, or risk of malignant transformation (IPMN-PC).
Ethical Concerns for Amnioinfusions—Reply
Authors: Omri D. Soffer, Teri J. Mauch, Melissa A. Muff-Luett
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial
Authors: Kristina Lend, Frieda A. Koopman, Jon Lampa, Gerrit Jansen, Merete L. Hetland, Till Uhlig, Dan Nordström, Michael Nurmohamed, Bjorn Gudbjornsson, Anna Rudin, Mikkel Østergaard, Marte S. Heiberg, Tuulikki Sokka‐Isler, Kim Hørslev‐Petersen, Espen A. Haavardsholm, Gerdur Grondal, Jos W. R. Twisk, Ronald van Vollenhoven
Journal: Arthritis & Rheumatology (2023)

We investigated methotrexate safety and the influence of dose on efficacy outcomes in combination with three different biologic treatments and with active conventional treatment (ACT) in early rheumatoid arthritis (RA).
Delineating a Role for Methionine Metabolism in Colorectal Cancer
Authors: Shiyu Liu, Jason W. Locasale
Journal: Cancer Research (2023)

Abstract Advances in mass spectrometry allow for broader applications of metabolomics in research and clinical applications. In a recent issue of Nature Metabolism, Vande Voorde and colleagues utilized metabolite profiling to investigate the metabolism of colorectal cancer in mouse models, organoids, and patients. This study underscores the utility of metabolomics in distinguishing colorectal cancer, offering potential for its use in precision medicine. It also revealed a pivotal role for adenosylhomocysteinase in the methionine cycle and highlighted its potential as a therapeutic target.
The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial
Authors: Franco Berrino, Anna Villarini, Giuliana Gargano, Vittorio Krogh, Sara Grioni, Manuela Bellegotti, Elisabetta Venturelli, Milena Raimondi, Adele Traina, Maurizio Zarcone, Rosalba Amodio, Maria Piera Mano, Harriet Johansson, Salvatore Panico, Maria Santucci de Magistris, Maggiorino Barbero, Cristina Gavazza, Angelica Mercandino, Elena Consolaro, Rocco Galasso, Luciana Del Riccio, Maria Chiara Bassi, Milena Simeoni, Paolo Premoli, Patrizia Pasanisi, Bernardo Bonanni, Eleonora Bruno
Journal: Clinical Cancer Research (2023)

Abstract Purpose: The DIANA-5 randomized controlled trial assessed the effectiveness of a diet based on Mediterranean and macrobiotic traditions (macro-Mediterranean diet) in reducing breast cancer recurrence. Patients and Methods: The DIANA-5 study involved 1,542 patients with breast cancer at high risk of recurrence because of estrogen receptor–negative cancer, or metabolic syndrome, or high plasma levels of insulin or testosterone. Women were randomly assigned to an active dietary intervention (IG) or a control group (CG). Both groups received the 2007 American Institute for Cancer Research/World Cancer Research Fund recommendations for cancer prevention. The intervention consisted of meetings with kitchen classes, community meals, and dietary recommendations. Recommended foods included whole grain cereals, legumes, soy products, vegetables, fruit, nuts, olive oil, and fish. Foods to be avoided were refined products, potatoes, sugar and desserts, red and processed meat, dairy products, and alcoholic drinks. A compliance Dietary Index was defined by the difference between recommended and discouraged foods. Results: Over the 5 years of follow-up, 95 patients of the IG and 98 of the CG developed breast cancer recurrence [HR = 0.99; 95% confidence interval (CI): 0.69–1.40]. The analysis by compliance to the dietary recommendations (IG and CG together) showed that the women in the upper tertile of Dietary Index change had an HR of recurrence of 0.59 (95% CI: 0.36–0.92) compared with women in the lower tertile. Conclusions: The DIANA-5 dietary intervention trial failed to show a reduction in breast cancer recurrence, although self-reported diet at year 1 in IG and CG combined showed a protective association with the higher Dietary Index change. See related commentary by McTiernan, p. 931
Error in Byline and Affiliations
Authors: Higgins Joyce, Robert Lurie
Journal: JAMA Network Open (2023)

Waheeda Samady, MD, MSci; Emily Campbell, MD; Ozge Nur Aktas, MD; Jialing Jiang, BA; Alexandria Bozen, BS; Jamie L. Fierstein, PhD; Alanna Higgins Joyce, MD, MSE; Ruchi S. Gupta, MD, MPH
Vitamin K Antagonists and Intracranial Hemorrhage After Endovascular Thrombectomy—Reply
Authors: Brian Mac Grory, Ying Xian
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selective Immunosuppression Targeting the NLRP3 Inflammasome Mitigates the Foreign Body Response to Implanted Biomaterials While Preserving Angiogenesis
Authors: Alex H.P. Chan, Matthew J. Moore, Angus J. Grant, Yuen Ting Monica Lam, Matthew V. Darnell, Praveesuda L. Michael, Steven G. Wise, Richard P. Tan
Journal: Advanced Healthcare Materials (2023)

Medical devices are a mainstay of the healthcare industry, providing clinicians with innovative tools to diagnose, monitor, and treat a range of medical conditions. For implantable devices, it is widely regarded that chronic inflammation during the foreign body response (FBR) is detrimental to device performance, but also required for tissue regeneration and host integration. Current strategies to mitigate the FBR rely on broad acting anti-inflammatory drugs, most commonly, dexamethasone (DEX), which can inhibit angiogenesis and compromise long-term device function. This study challenges prevailing assumptions by suggesting that FBR inflammation is multifaceted, and selectively targeting its individual pathways can stop implant fibrosis while preserving beneficial repair pathways linked to improved device performance. MCC950, an anti-inflammatory drug that selectively inhibits the NLRP3 inflammasome, targets pathological inflammation without compromising global immune function. The effects of MCC950 and DEX on the FBR are compared using implanted polycaprolactone (PCL) scaffolds. The results demonstrate that both DEX and MCC950 halt immune cell recruitment and cytokine release, leading to reduced FBR. However, MCC950 achieves this while supporting capillary growth and enhancing tissue angiogenesis. These findings support selective immunosuppression approaches as a potential future direction for treating the FBR and enhancing the longevity and safety of implantable devices.
A brain-tumor neural circuit controls breast cancer progression in mice
Authors: Si-Yi Xiong, Hui-Zhong Wen, Li-Meng Dai, Yun-Xiao Lou, Zhao-Qun Wang, Yi-Lun Yi, Xiao-Jing Yan, Ya-Ran Wu, Wei Sun, Peng-Hui Chen, Si-Zhe Yang, Xiao-Wei Qi, Yi Zhang, Guang-Yan Wu
Journal: Journal of Clinical Investigation (2023)

Tumor burden, considered a common chronic stressor, can cause widespread anxiety. Evidence suggests that cancer-induced anxiety can promote tumor progression, but the underlying neural mechanism remains unclear. Here, we used neuroscience and cancer tools to investigate how the brain contributes to tumor progression via nerve-tumor crosstalk in mice model of breast cancer. We showed that the tumor-bearing mice exhibited significant anxiety-like behaviors and that corticotropin-releasing hormone (CRH) neurons in the central medial amygdala (CeM) were activated. Moreover, newly formed sympathetic nerves were detected in tumors, which established a polysynaptically connected with the brain. Pharmacogenetic or optogenetic inhibition of CeMCRH neurons and CeMCRH→LPGi circuit significantly alleviated anxiety-like behaviors and slowed tumor growth. Conversely, artificial activation of CeMCRH neurons and CeMCRH→LPGi circuit increased anxiety and tumor growth. Importantly, alprazolam, an anti-anxiety drug, was found to be a promising intervention for slowing tumor progression. Furthermore, we showed that manipulation of CeMCRH→LPGi circuit directly regulates the activity of the intratumoral sympathetic nerves and peripheral nerve-derived norepinephrine, then affecting tumor progression by modulating the antitumor immunity. Together, these findings reveal a brain–tumor neural circuit contributing to breast cancer progression and provide new therapeutic insights for breast cancer.
Images of the Week
Authors: Wendy Stead
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vitamin K Antagonists and Intracranial Hemorrhage After Endovascular Thrombectomy
Authors: Arosh S. Perera Molligoda Arachchige
Journal: JAMA (2023)

To the Editor I have some concerns about the recent article1 that investigated whether recent exposure to vitamin K antagonists (VKAs) in patients with acute ischemic stroke selected to undergo endovascular thrombectomy (EVT) increased the risk of symptomatic intracranial hemorrhage (sICH).
Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate
Authors: Jinge Zhao, Nanwei Xu, Sha Zhu, Ling Nie, Mengni Zhang, Linmao Zheng, Diming Cai, Xiaomeng Sun, Junru Chen, Jindong Dai, Yuchao Ni, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Yuntian Chen, Xu Hu, Xiuyi Pan, Xiaoxue Yin, Haoyang Liu, Fengnian Zhao, Bei Zhang, Hao Chen, Jiashun Miao, Cong Qin, Xiaochen Zhao, Jin Yao, Zhenhua Liu, Banghua Liao, Qiang Wei, Xiang Li, Jiyan Liu, Allen C. Gao, Haojie Huang, Pengfei Shen, Ni Chen, Hao Zeng, Guangxi Sun
Journal: Cancer Research (2023)

Abstract Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that generally coexists with invasive high-grade prostate acinar adenocarcinoma (PAC) but exhibits distinct biological features compared with concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing of IDC-P, concurrent invasive high-grade PAC lesions, and adjacent normal prostate tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns of concurrent IDC-P and PAC were identified: early divergent, late divergent, and clonally distant. In contrast to those with a late divergent evolutionary pattern, tumors with clonally distant and early divergent evolutionary patterns showed higher genomic, epigenomic, transcriptional, and pathologic heterogeneity between IDC-P and PAC. Compared with coexisting PAC, IDC-P displayed increased expression of adverse prognosis–associated genes. Survival analysis based on an independent cohort of 505 patients with metastatic prostate cancer revealed that IDC-P carriers with lower risk International Society of Urological Pathology (ISUP) grade 1–4 adenocarcinoma displayed a castration-resistant free survival as poor as those with the highest risk ISUP grade 5 tumors that lacked concurrent IDC-P. Furthermore, IDC-P exhibited robust cell-cycle progression and androgen receptor activities, characterized by an enrichment of cellular proliferation–associated master regulators and genes involved in intratumoral androgen biosynthesis. Overall, this study provides a molecular groundwork for the aggressive behavior of IDC-P and could help identify potential strategies to improve treatment of IDC-P. Significance: The genomic, transcriptomic, and epigenomic characterization of concurrent intraductal carcinoma and adenocarcinoma of the prostate deepens the biological understanding of this lethal disease and provides a genetic basis for developing targeted therapies.
Ethical Concerns for Amnioinfusions
Authors: Meredith A. Atkinson, Jena L. Miller
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Million Hearts Cardiovascular Disease Risk Reduction Model
Authors: Gabriel S. Tajeu, Karen Joynt Maddox, LaPrincess C. Brewer
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased 18F-FAPI-04 Uptake in Vertebral Hemangioma
Authors: Jing-Yun Ren, Qing Zhang, Peng Wang, Lei Jiang, En-Tao Liu
Journal: Clinical Nuclear Medicine (2023)

Abstract A 54-year-old man with a history of colectomy for colorectal cancer and subsequent liver metastasectomy underwent 18 F-FDG PET/CT and 18 F-FAPI-04 PET/CT scans to evaluate possible hepatic metastasis revealed by contrast-enhanced MRI. Both studies showed similarly increased uptake in liver metastases, and 18 F-FDG detected a metastatic lung nodule. Furthermore, the images showed an incidental finding of increased uptake of 18 F-FAPI-04 in the L3 vertebral, which was not 18 F-FDG–avid. A review of the patient's previous CT and MRI scans suggests vertebral hemangioma.